Cargando…
39. Anti-Spike Monoclonal Antibody Therapy for Kidney Transplant Recipients with COVID-19
BACKGROUND: Organ transplant recipients may not mount an adequate immune response to COVID-19 infection, and therefore may benefit greatly from passive immunization with anti-spike monoclonal antibodies (mAb), which have been shown to decrease hospitalization rates in the general outpatient populati...
Autores principales: | Hardesty, Anna, Klein, Elizabeth, Vieira, Kendra, Farmakiotis, Dimitrios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644697/ http://dx.doi.org/10.1093/ofid/ofab466.039 |
Ejemplares similares
-
530. COVID-19 in kidney transplant recipients: Single-center experience and case-control study
por: Hardesty, Anna, et al.
Publicado: (2020) -
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
por: Arvanitis, Panos, et al.
Publicado: (2023) -
Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19
por: Arvanitis, Panos, et al.
Publicado: (2023) -
Comparison of COVID-19 outcomes in organ transplant recipients (OTr) and non-transplant patients: a study protocol for rapid review
por: Lerner, Alexis H., et al.
Publicado: (2021) -
Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control Study
por: Hardesty, Anna, et al.
Publicado: (2021)